Hybio Pharmaceutical Co., Ltd.

SZSE:300199 Stock Report

Market Cap: CN¥10.2b

Hybio Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Hybio Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth18.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Sep 30
Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Jul 20
Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Jun 03
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Feb 29
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

Feb 26
Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hybio Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300199 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024405-36860139N/A
6/30/2024362-490767N/A
3/31/2024405-547-1849N/A
12/31/2023431-514-85-4N/A
9/30/2023575-404-158-46N/A
6/30/2023673-306-239-53N/A
3/31/2023713-294-238-42N/A
1/1/2023704-371-17416N/A
9/30/20227592-14035N/A
6/30/2022726-41-6995N/A
3/31/2022725-50-69107N/A
1/1/202273631-42157N/A
9/30/2021542-783-110143N/A
6/30/2021648-683-12881N/A
3/31/2021708-608-89157N/A
12/31/2020722-609-19648N/A
9/30/2020745-749-63291N/A
6/30/2020604-914-343108N/A
3/31/2020613-914-48458N/A
12/31/2019614-885-466105N/A
9/30/2019916-714-807-297N/A
6/30/20191,068-474-4641N/A
3/31/20191,189-387-425-44N/A
1/1/20191,264-341-31947N/A
9/30/20181,43738944367N/A
6/30/20181,414379N/A336N/A
3/31/20181,309350N/A337N/A
12/31/20171,246330N/A229N/A
9/30/2017955296N/A302N/A
6/30/2017990342N/A245N/A
3/31/2017894312N/A346N/A
12/31/2016855292N/A296N/A
9/30/2016926361N/A177N/A
6/30/2016846326N/A166N/A
3/31/2016813326N/A71N/A
12/31/2015768305N/A139N/A
9/30/2015592241N/A124N/A
6/30/2015527212N/A149N/A
3/31/2015475188N/A162N/A
12/31/2014419172N/A153N/A
9/30/2014400166N/A133N/A
6/30/2014342138N/A162N/A
3/31/2014321133N/A155N/A
12/31/2013301130N/A153N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300199's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 300199's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300199's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300199's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300199's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 300199's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y